J
-
Bayer HealthCare, Tsinghua University in partnership
Both partners signed a new strategic agreement to collaborate in the area of biomedical sciences over the next three years.
J | 07 May 2012
-
China remains one of the fastest growing pharmaceutical markets in the world
China and Japan will be the largest and second largest pharmaceutical markets in the Asia Pacific region in 2016.
J | 27 April 2012
-
Pharmaceutical companies from Japan, India and China are amongst Asia Pacific’s most innovative
Pharmaceutical companies from Japan, India and China were among Asia Pacific’s leading innovators last year according to one of two reports released by Thomson Reuters, which provide new insights into global patent and trademark trends throughout 2011.
J | 28 March 2012
-
Major IT trends shaping life sciences in 2012
Three IT trends will shape the life sciences in 2012, according to an analysis by SAFE-BioPharma Association. They are the expanded use of standards-based interoperable digital identities, cloud computing in clinical trials, and the use of electronic trial master files for clinical trial management.
J | 23 March 2012
-
JSR expands biomedical business
JSR Corporation and BIA Separations announced that they have entered a partnership which includes a minor equity position by JSR.
J | 29 February 2012
-
Agilent Technologies joins sponsors of GreenCentre Canada
Agilent Technologies has joined the sponsors of GreenCentre Canada, a national centre of excellence for commercializing green chemistry discoveries generated by academic researchers and industry.
J | 30 January 2012
-
ICON Acquires BeijingWits Medical Consulting
ICON has agreed, subject to closing conditions, to acquire BeijingWits Medical Consulting, a leading CRO in China. The transaction is expected to close in the first quarter of 2012.
J | 11 January 2012
-
Vorapaxar’s data presented at AHA, published in NEJM
Researchers presented and published results from TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome), the first clinical outcomes trial of vorapaxar, the investigational Protease Activated Receptor 1 (PAR-1) thrombin receptor antagonist from Merck (known as MSD outside the US and Canada).
J | 18 November 2011
-
Bayer’s Xarelto (Rivaroxaban) meets primary efficacy endpoint, shows significant reduction in mortality in major study
Bayer HealthCare announced that the combination of oral Xarelto (Rivaroxaban) twice daily with standard antiplatelet therapy significantly reduced the composite primary efficacy endpoint of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome (ACS) compared to those receiving standard antiplatelet therapy alone.
J | 17 November 2011
-
S*BIO to initiate global phase 3 clinical trials of its novel JAK2 inhibitor
S*BIO explores partnering opportunities for advancement of its JAK2 program.
J | 25 October 2011
